» Articles » PMID: 27543611

Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens Against Virulent Francisella Tularensis

Overview
Journal J Immunol
Date 2016 Aug 21
PMID 27543611
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

T cells are the immunological cornerstone in host defense against infections by intracellular bacterial pathogens, such as virulent Francisella tularensis spp. tularensis (Ftt). The general paucity of novel vaccines for Ftt during the past 60 y can, in part, be attributed to the poor understanding of immune parameters required to survive infection. Thus, we developed a strategy utilizing classical immunological tools to elucidate requirements for effective adaptive immune responses directed against Ftt. Following generation of various Francisella strains expressing well-characterized lymphocytic choriomeningitis virus epitopes, we found that survival correlated with persistence of Ag-specific CD4(+) T cells. Function of these cells was confirmed in their ability to more effectively control Ftt replication in vitro. The importance of understanding the Ag-specific response was underscored by our observation that inclusion of an epitope that elicits high-avidity CD4(+) T cells converted a poorly protective vaccine to one that engenders 100% protection. Taken together, these data suggest that improved efficacy of current tularemia vaccine platforms will require targeting appropriate Ag-specific CD4(+) T cell responses and that elucidation of Francisella epitopes that elicit high-avidity CD4(+) T cell responses, specifically in humans, will be required for successful vaccine development.

Citing Articles

A glucan-particle based tularemia subunit vaccine induces T-cell immunity and affords partial protection in an inhalation rat infection model.

Whelan A, Flick-Smith H, Walker N, Abraham A, Levitz S, Ostroff G PLoS One. 2024; 19(5):e0294998.

PMID: 38713688 PMC: 11075878. DOI: 10.1371/journal.pone.0294998.


Contribution of Lipid Mediators in Divergent Outcomes following Acute Bacterial and Viral Lung Infections in the Obese Host.

Schwarz B, Roberts L, Bohrnsen E, Jessop F, Wehrly T, Shaia C J Immunol. 2022; 209(7):1323-1334.

PMID: 36002235 PMC: 9529825. DOI: 10.4049/jimmunol.2200162.


Working correlates of protection predict SchuS4-derived-vaccine candidates with improved efficacy against an intracellular bacterium, Francisella tularensis.

De Pascalis R, Frey B, Rice H, Bhargava V, Wu T, Peterson R NPJ Vaccines. 2022; 7(1):95.

PMID: 35977964 PMC: 9385090. DOI: 10.1038/s41541-022-00506-9.


Circulating T Cells Are Not Sufficient for Protective Immunity against Virulent .

Roberts L, Wehrly T, Leighton I, Hanley P, Lovaglio J, Smith B J Immunol. 2022; 208(5):1180-1188.

PMID: 35149529 PMC: 8881340. DOI: 10.4049/jimmunol.2100915.


Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses.

Natrajan M, Rouphael N, Lai L, Kazmin D, Jensen T, Weiss D Vaccines (Basel). 2019; 8(1).

PMID: 31878161 PMC: 7158697. DOI: 10.3390/vaccines8010004.


References
1.
Yee D, Elkins K . Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol. 1996; 157(11):5042-8. View

2.
Crane D, Scott D, Bosio C . Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS One. 2012; 7(3):e33349. PMC: 3299770. DOI: 10.1371/journal.pone.0033349. View

3.
Griffin A, Crane D, Wehrly T, Bosio C . Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells. Clin Vaccine Immunol. 2014; 22(1):119-28. PMC: 4278928. DOI: 10.1128/CVI.00648-14. View

4.
Welsh R, Seedhom M . Lymphocytic choriomeningitis virus (LCMV): propagation, quantitation, and storage. Curr Protoc Microbiol. 2008; Chapter 15:Unit 15A.1. PMC: 3220596. DOI: 10.1002/9780471729259.mc15a01s8. View

5.
Oxenius A, Bachmann M, Ashton-Rickardt P, Tonegawa S, Zinkernagel R, Hengartner H . Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Eur J Immunol. 1995; 25(12):3402-11. DOI: 10.1002/eji.1830251230. View